Study guide
4.3 Diabetes Mellitus: Diagnosis, Complications & Management
Combined Medical Services Examination UPSC CMS
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Logistics & Pattern
1.1 UPSC CMS Examination Overview & Eligibility 1.2 Two-Paper Written Exam Pattern & Negative Marking 1.3 Personality Test, Service Allocation & Career Paths
2 Chapter 2: General Medicine - Cardiology & Respiratory
2.1 Coronary Artery Disease & Acute Myocardial Infarction 2.2 Heart Failure & Cardiac Arrhythmias 2.3 Community-Acquired Pneumonia & Pulmonary Tuberculosis 2.4 COPD, Bronchial Asthma & Pulmonary Embolism
3 Chapter 3: General Medicine - Gastroenterology & Hepatology
3.1 Peptic Ulcer Disease & Upper GI Bleeding 3.2 Liver Cirrhosis & Portal Hypertension 3.3 Acute & Chronic Viral Hepatitis & Pancreatitis 3.4 Inflammatory Bowel Disease & Malabsorption Syndromes
4 Chapter 4: General Medicine - Nephrology & Endocrinology
4.1 Acute Kidney Injury & Chronic Kidney Disease 4.2 Glomerulonephritis, Nephrotic Syndrome & Electrolyte Imbalances 4.3 Diabetes Mellitus: Diagnosis, Complications & Management 4.4 Thyroid Disorders & Adrenal Gland Dysfunction
5 Chapter 5: General Medicine - Neurology, Haematology & Infection
5.1 Cerebrovascular Accidents (Stroke) & Epilepsy 5.2 Approach to Anaemia: Microcytic, Megaloblastic & Haemolytic 5.3 Acute & Chronic Leukaemias and Lymphomas 5.4 Tropical & Endemic Infections: Malaria, Typhoid & Dengue
6 Chapter 6: General Medicine - Emergency Medicine & Toxicology
6.1 Acute Anaphylaxis, Sepsis & Cardiopulmonary Resuscitation 6.2 Organophosphate, Paracetamol & Snakebite Toxicology 6.3 Common Dermatological & Psychiatric Manifestations in Internal Medicine 6.4 Musculoskeletal System & Adult Rheumatology
7 Chapter 7: Paediatrics - Neonatology & Child Growth
7.1 Newborn Care, Neonatal Resuscitation & APGAR Score 7.2 Prematurity, Low Birth Weight & Neonatal Jaundice 7.3 Infant & Child Growth & Developmental Milestones
8 Chapter 8: Paediatrics - Child Health & Nutrition
8.1 Protein-Energy Malnutrition (PEM) & Micronutrient Deficiencies 8.2 Universal Immunization Programme (UIP) & Child Vaccines 8.3 Pediatric Diarrhoea, Dehydration & Respiratory Emergencies 8.4 Birth Defects, Genetic Counseling, Autism & Paediatric Accidents/Poisoning
9 Chapter 9: Surgery - General Surgery, Wounds & Shock
9.1 Wound Healing, Surgical Site Infections & Gas Gangrene 9.2 Pathophysiology of Shock & Perioperative Fluid Therapy 9.3 Acute Abdomen: Appendicitis, Peritonitis & Intestinal Obstruction 9.4 Classification, Resuscitation & Management of Thermal Burns 9.5 Medicolegal & Ethical Issues in Surgery
10 Chapter 10: Surgery - Surgical Specialties I
10.1 Inguinal, Femoral & Ventral Hernias 10.2 Benign Breast Diseases & Breast Carcinoma 10.3 Solitary Thyroid Nodule & Thyroid Carcinoma 10.4 Benign Prostatic Hyperplasia & Renal Calculi
11 Chapter 11: Surgery - ENT, Orthopaedics & Anaesthesia
11.1 Acute Otitis Media, Tonsillitis & Epistaxis 11.2 Cataract, Glaucoma & Red Eye Emergencies 11.3 Principles of Fracture Management & Common Dislocation 11.4 Principles of Local, Regional & General Anaesthesia 11.5 Neurosurgery: Raised ICP, Head Injury & CNS Lesions 11.6 Thoracic Surgery: Chest Trauma, Pleural & Lung Disease
12 Chapter 12: Obstetrics - Antenatal Care & Complications
12.1 Antenatal Care, Maternal Nutrition & Fetal Assessment 12.2 Preeclampsia, Eclampsia & Gestational Hypertension 12.3 Antepartum Haemorrhage: Placenta Previa & Abruptio Placentae 12.4 Anemia in Pregnancy & Gestational Diabetes Mellitus 12.5 Spontaneous & Recurrent Abortion: Recognition & Management
13 Chapter 13: Obstetrics & Gynaecology - Labor & PPH
13.1 Normal Labor Mechanisms & Partograph Monitoring 13.2 Malpresentations, Breech & Obstructed Labor 13.3 Postpartum Haemorrhage (PPH) Causes & Management 13.4 Puerperal Sepsis & Postnatal Maternal Care
14 Chapter 14: Gynaecology & Family Planning
14.1 Abnormal Uterine Bleeding & Uterine Fibroids 14.2 Cervical Screening (Pap Smear) & Pelvic Inflammatory Disease 14.3 Temporary & Permanent Contraceptive Methods in India 14.4 Medical Termination of Pregnancy (MTP): Law & Methods
15 Chapter 15: PSM - Epidemiology & Biostatistics
15.1 Principles of Epidemiology & Disease Transmission 15.2 Observational & Experimental Epidemiological Study Designs 15.3 Evaluation of Screening Tests: Sensitivity, Specificity & Predictive Value 15.4 Biostatistics: Sampling, Central Tendency & Significance Testing
16 Chapter 16: PSM - Disease Epidemiology & Programmes
16.1 Epidemiology & Control of TB, Malaria & Dengue 16.2 National Tuberculosis Elimination Programme & NVBDCP 16.3 Epidemiology of Hypertension, Diabetes & Cancer in India 16.4 Cold Chain Management & Vaccine Logistics in India 16.5 Genetics and Health: Inheritance, Screening & Counseling
17 Chapter 17: PSM - Health Planning & Environmental Health
17.1 Demography, Fertility Rates & Family Welfare Indicators 17.2 Safe Water Supply, Waste Disposal & Air Pollution 17.3 Occupational Health Hazards & Pneumoconioses 17.4 Health Care Delivery System, Ayushman Bharat & National Health Mission 17.5 International Health: WHO, Global Agencies & SDG 3 17.6 Medical Sociology & Health Education
4.3 Diabetes Mellitus: Diagnosis, Complications & Management
Key Takeaways Explain This Topic AI
Diabetes Mellitus diagnostic thresholds: Fasting Plasma Glucose ≥126 mg/dL, 2-hour OGTT ≥200 mg/dL, HbA1c ≥6.5%, or Random Plasma Glucose ≥200 mg/dL with classic hyperglycemic symptoms.
Diabetic Ketoacidosis (DKA) is defined by hyperglycemia (>250 mg/dL), high anion gap metabolic acidosis (pH <7.30, HCO3 <18 mEq/L), and serum/urine hyperketonemia, requiring IV normal saline, regular insulin, and strict potassium repletion.
Hyperosmolar Hyperglycemic State (HHS) presents with extreme hyperglycemia (>600 mg/dL), high effective serum osmolality (>320 mOsm/kg), and minimal acidosis, requiring aggressive fluid resuscitation.
Metformin is the initial drug of choice for Type 2 Diabetes but is contraindicated when eGFR <30 mL/min/1.73 m² due to lactic acidosis risk.
SGLT2 inhibitors (Empagliflozin, Dapagliflozin) provide proven cardiorenal protection and reduce heart failure hospitalizations, while GLP-1 receptor agonists (Semaglutide, Liraglutide) reduce major adverse cardiovascular events (MACE) and promote significant weight loss.
Last updated: July 2026
Diabetes Mellitus: Diagnosis, Complications & Management
Diabetes Mellitus is one of the most frequently tested topics in UPSC CMS General Medicine. Candidates must master diagnostic cut-offs, acute crisis management protocols (DKA vs HHS), microvascular organ protection, and guideline-directed pharmacotherapy.
1. Diagnostic Criteria & Screening Guidelines
According to the American Diabetes Association (ADA) guidelines, the diagnosis of Diabetes Mellitus requires fulfilling any one of the four standardized criteria:
- Diagnostic Category Fasting Plasma Glucose (FPG) 2-Hour OGTT (75g glucose) HbA1c Level Random Plasma Glucose
- Normal <100 mg/dL (5.6 mmol/L) <140 mg/dL (7.8 mmol/L) <5.7% —
- Prediabetes 100–125 mg/dL ( IFG ) 140–199 mg/dL ( IGT ) 5.7% – 6.4% —
Diabetes Mellitus ≥126 mg/dL (7.0 mmol/L) ≥200 mg/dL (11.1 mmol/L) ≥6.5% (NGSP certified) ≥200 mg/dL + Classic Symptoms
Diagnostic Rules :
Fasting is defined as no caloric intake for at least 8 hours.
In the absence of unequivocal hyperglycemia (e.g., hyperglycemic crisis or classic symptoms of polyuria, polydipsia, unexplained weight loss), diagnosis requires two abnormal test results from the same sample or two separate test samples.
2. Acute Hyperglycemic Crises: DKA vs. HHS
Diabetic Ketoacidosis (DKA) and Hyperosmolar Hyperglycemic State (HHS) are life-threatening endocrine emergencies. DKA occurs predominantly in Type 1 DM due to absolute insulin deficiency, whereas HHS occurs in Type 2 DM (especially elderly, impaired thirst response) due to relative insulin deficiency.
- Clinical Parameter Diabetic Ketoacidosis (DKA) Hyperosmolar Hyperglycemic State (HHS)
- Primary Population Type 1 Diabetes Mellitus Type 2 Diabetes Mellitus (Elderly)
- Blood Glucose >250 mg/dL (usually 300–600 mg/dL) >600 mg/dL (often >1000 mg/dL)
- Arterial pH <7.30 (Mild 7.25–7.30, Mod 7.00–7.24, Severe <7.00) >7.30 (Normal or mild acidosis)
- Serum Bicarbonate <18 mEq/L (Severe <10 mEq/L) >18 mEq/L
- Ketones (Serum/Urine) Strongly Positive (Beta-hydroxybutyrate) Absent or Trace
- Serum Osmolality Variable (<320 mOsm/kg) >320 mOsm/kg (Extreme Hyperosmolality)
- Anion Gap High Anion Gap (>12 mEq/L) Variable / Normal
- Respiration Kussmaul breathing (deep, rapid) with fruity acetone odor Normal or shallow
- Mental Status Alert to lethargic Stupor or Coma
- Acute Management Protocol for DKA
Fluid Resuscitation (First Priority) : 0.9% Normal Saline (1.0–1.5 L in the 1st hour). Switch to 0.45% NaCl once corrected serum sodium is normal or high. Add 5% Dextrose when blood glucose reaches 200–250 mg/dL to prevent cerebral edema and allow continued insulin for ketoacidosis clearance.
Insulin Therapy : IV Regular Insulin 0.1 Units/kg bolus , followed by 0.1 Units/kg/hour continuous infusion (or 0.14 U/kg/h without bolus). Target BG reduction rate: 50–75 mg/dL per hour.
Potassium Repletion (CRITICAL) :
Check K⁺ before initiating insulin .
If K⁺ <3.3 mEq/L : HOLD INSULIN and give IV KCl (20–30 mEq/h) until K⁺ >3.3 mEq/L (insulin shifts K⁺ into cells and can trigger fatal arrhythmia).
If K⁺ 3.3–5.3 mEq/L : Add 20–30 mEq K⁺ per liter of IV fluid to maintain serum K⁺ between 4.0–5.0 mEq/L.
If K⁺ >5.3 mEq/L : Do not add K⁺; recheck every 2 hours.
Bicarbonate : Indicated ONLY if pH <6.90 .
Loading diagram... Hyperglycemic Emergency (DKA/HHS) Management Algorithm
- 3. Chronic Microvascular & Macrovascular Complications
- A. Diabetic Retinopathy
Non-Proliferative Diabetic Retinopathy (NPDR) : Microaneurysms (earliest clinical sign), hard exudates (lipid deposits), cotton-wool spots (nerve fiber layer microinfarctions), intraretinal hemorrhages ("dot and blot").
Proliferative Diabetic Retinopathy (PDR) : Marked by Neovascularization (formation of new vessel growth driven by retinal ischemia and VEGF elevation). Complications: Vitreous hemorrhage, tractional retinal detachment, neovascular glaucoma.
Screening : Type 1 DM (5 years after diagnosis); Type 2 DM (at diagnosis).
Treatment : Anti-VEGF intravitreal injections (Ranibizumab, Aflibercept) and Panretinal Photocoagulation (PRP) .
B. Diabetic Nephropathy
Progression: Glomerular hyperfiltration → Moderately increased albuminuria (30–300 mg/day) → Severely increased albuminuria (>300 mg/day) → Progressive GFR decline.
Histology: Diffuse glomerulosclerosis and pathognomonic Kimmelstiel-Wilson nodules (nodular intercapillary glomerulosclerosis, PAS-positive).
Treatment: First-line agents to retard progression are ACE inhibitors / ARBs (reduce intraglomerular pressure by dilating efferent arterioles) and SGLT2 inhibitors .
C. Diabetic Neuropathy
Distal Symmetric Polyneuropathy : Most common form. Progressive sensory loss in a classic "glove-and-stocking" distribution (vibration and position sense affected first, followed by pain and temperature).
Autonomic Neuropathy : Resting tachycardia, orthostatic hypotension, gastroparesis (treated with Metoclopramide or Erythromycin), neurogenic bladder, erectile dysfunction.
Neuropathic Pain Pharmacotherapy : First-line agents include Pregabalin , Gabapentin , or Duloxetine .
4. Antidiabetic Pharmacotherapy & Guideline Algorithms
Class Major Drugs Mechanism of Action Clinical Advantages / Indications Key Side Effects & Contraindications
Biguanides Metformin Decreases hepatic gluconeogenesis; increases peripheral insulin sensitivity First-line agent; weight neutral; no hypoglycemia GI upset, Vit B12 deficiency, Lactic Acidosis . Contraindicated if eGFR <30 mL/min/1.73 m²
SGLT2 Inhibitors Empagliflozin , Dapagliflozin Inhibits SGLT2 in proximal convoluted tubule → glucosuria Proven Cardiorenal protection (reduces HF hospitalizations & CKD progression); weight loss Mycotic genital infections, UTIs, Euglycemic DKA , volume depletion
GLP-1 Receptor Agonists Semaglutide , Liraglutide , Dulaglutide Incretin mimetic: glucose-dependent insulin secretion, slows gastric emptying Major reduction in ASCVD MACE events ; profound weight loss Nausea, vomiting, pancreatitis risk, C-cell thyroid tumor risk (MEN2 contraindication)
DPP-4 Inhibitors Sitagliptin , Linagliptin Prevents degradation of endogenous GLP-1 Weight neutral; low hypoglycemia risk; Linagliptin requires no renal dose adjustment Pancreatitis, joint pain; Saxagliptin increases HF risk
Sulfonylureas Glimepiride , Gliclazide Closes K-ATP channels on pancreatic beta cells → insulin secretagogue Potent glucose lowering; low cost Hypoglycemia , weight gain
Thiazolidinediones Pioglitazone PPAR-gamma agonist; enhances peripheral insulin sensitivity No hypoglycemia Fluid retention/Edema, Contraindicated in Heart Failure (NYHA III/IV) , bone fractures